Altered amyloid precursor protein (APP) processing potentiates the aggregation of glycation products, and amyloid-β (Aβ) toxicity is a key pathogenic feature of Alzheimer’s disease (AD) [91,92]. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.